Two selected trials address cardiovascular outcomes in type 2 diabetes and exploratory motor outcomes in early Parkinson disease. These are lixisenatide trials, not evidence for the insulin-glargine combination as an interchangeable intervention.12
Bottom line from this bounded source set
ELIXA met cardiovascular noninferiority but did not demonstrate cardiovascular superiority. A smaller Parkinson trial reported less motor-score worsening over 12 months, with gastrointestinal adverse effects; it does not establish neuroprotection or a new approved indication.12
Reviewed study record
ELIXA: cardiovascular outcomes
Design
Randomized placebo-controlled trial added lixisenatide or placebo to usual care.1
Population
6,068 people with type 2 diabetes and a recent acute coronary event were followed for a median of 25 months.1
Outcomes reported
The primary cardiovascular composite occurred in 13.4% versus 13.2%; hazard ratio 1.02 (95% CI 0.89–1.17). Noninferiority was met, superiority was not. Serious adverse events were not more frequent with lixisenatide.1
Limitations
The result is a cardiovascular safety comparison in a high-risk population, not evidence of cardiovascular benefit or the entire glycemic-efficacy program.1
Reviewed study record
LIXIPARK: exploratory Parkinson trial
Design
Randomized, double-blind, placebo-controlled phase 2 trial with 12 months of treatment and a two-month washout.2
Population
156 people with early Parkinson disease were randomized while receiving stable symptomatic therapy.2
Outcomes reported
The between-group difference in motor-score change at 12 months was 3.08 points favoring lixisenatide. Nausea occurred in 46% and vomiting in 13% of active-group participants.2
Limitations
The primary assessment was in the on-medication state. A small phase 2 study cannot establish disease modification, long-term benefit or safety; larger trials are required.2
No registered Crossref update in the reviewed snapshotChecked September 15, 2026 for DOI 10.1056/nejmoa1509225. This bounded result is not proof that the publication has never been corrected or retracted. Open the pinned Crossref work endpoint ↗
No registered Crossref update in the reviewed snapshotChecked September 15, 2026 for DOI 10.1056/nejmoa2312323. This bounded result is not proof that the publication has never been corrected or retracted. Open the pinned Crossref work endpoint ↗